Commercial Strategies
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

A Next-Gen Approach To Health Care Risk And Compliance
Across the health care industry, the increasing numbers of ethics violations, data breaches and reputational challenges reflect the growing magnitude and prevalence of compliance failures.

Spinning Around – One Company's Bid To Diagnostic-ify The Metabolism
Lifespin is working on tools to characterize a patient’s metabolism and provide more detailed information about a disease.

Abbott Buys Bigfoot Biomedical – But What Lurks In The Forest?
Abbott and Bigfoot Biomedical have worked as partners for more than half a decade but will now continue as one. Analysts are questioning whether the merger will simply be a tuck-in for Abbott, or enable it to release an insulin pump of their own.

After All The Layoffs, Is Biopharma’s Headcount Still Growing?
While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.

HSBC Innovation Expects Settled Life Science Market By End Of 2024
Michael White, the new UK head of life sciences at HSBC Innovation Banking, made the move from California to join the UK group shortly before Silicon Valley Bank in London collapsed in March 2023. He talks to In Vivo about turbulent life science markets and the future life sciences strategy at HSBC.

PacBio Scores Hat Trick Of Big News To Start August
A jump in earnings, the acquisition of Apton and the launch of the long-awaited Onso sequencing system – all in one week at Pacific Biosciences.

Healthcare Reform: GE HealthCare On ‘Building A Bridge To The Future State’
System interoperability and building trust in AI capabilities are central to the strategic collaboration and organic growth plans at GE HealthCare, according to US and Canada regional president and CEO Catherine Estrampes, who spoke to In Vivo as the company released the findings of a major survey of clinicians and patients on future healthcare system needs.

Intuitive Surgical Sees Procedure Volume Surge; Drug Competition Threatens Bariatric Business
The robotic surgery giant reported rapid procedure growth across all surgical division except bariatrics, worrying some investors.

It’s Time For A Billion-Dollar Women's Health Fund
Jessica Federer, former chief digital officer at Bayer, talks to In Vivo about making the jump into investing and why women’s health is a rich and deep market set for change.

With Strong Anti-Inflammatory Candidate In Hand, Abivax Execs Carve A Path Forward
With a strong late-stage anti-inflammatory molecule in its pipeline, the challenge for Abivax is to garner the funds to take its obefazimod program forward. To that end, the company is continuing to do a major overhaul of personnel and is sharpening its corporate vision.

Pressure Mounts On Pharma To Act On Environmental Targets
There are growing demands from government officials, investors and employees for the pharmaceutical industry to reduce emissions and waste, and – most of all – make environmental sustainability a core part of its business.

Minute Insight: Coloplast Adds Icelandic Wound Care Innovator Kerecis For $1.3BN
Coloplast expects Kerecis' rapid growth to justify the high price of the acquisition. The Icelandic company's skin-substitute products are made from minimally processed cod skins.

Dealmaking Gives Biotechs Needed Financial Relief, But Deal Terms Are Under Pressure
Biotechs are ready to partner or sell assets to raise cash while turmoil continues in the financial markets, but they are doing so at lower valuations, with IRA and FTC concerns putting further pressure on deal terms.

Boehringer Ingelheim’s Pagnotta On Adalimumab And Interchangeability
As Boehringer Ingelheim launches the first – and so far, only – interchangeable US adalimumab biosimilar, the firm’s biosimilar commercial brand lead Stephen Pagnotta talks about how the interchangeability designation puts the firm in a unique position when it comes to competing with Humira.

What Do They Want? Securing The Big Pharma Deal
Partnering has changed in many ways in the last 18 months. Financial markets have all but closed to start-ups and investors are consolidating asset bases in the expectation of relatively high inflation continuing for the next few years.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.